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Danggui BuxueTang (DBT), a herbal decoction containingAstragali Radix (AR) andAngelicae Sinensis Radix (ASR), has been used
in treatingmenopausal irregularity inwomen formore than 800 years inChina. Pharmacological results showed thatDBT exhibited
significant estrogenic properties in vitro, which therefore suggested that DBT could activate the nuclear estrogen receptors. Here,
we assessed the estrogenic properties of DBT in an ovariectomized in vivo rat model: DBT was applied to the ovariectomized rats
for 3 days.The application of DBT did not alter the weight of uterus and liver, as well as the transcript expression of the proliferation
markers including the estrogen receptors 𝛼 and 𝛽. However, DBT stimulated the transcript expression of the estrogen responsive
genes. In addition, the inductive role of DBT on the expression of members of the aryl hydrocarbon receptor family in uterus
and liver of ovariectomized rats was confirmed. These responses of DBT however were clearly distinct from the response pattern
detectable here for 17𝛽-estradiol.Therefore, DBT exhibited weak, but significant, estrogenic properties in vivo; however, some of its
activities were independent of the estrogen receptor. Thus, DBT could be an exciting Chinese herbal decoction for an alternative
treatment of hormone replacement therapy for women in menopause without subsequent estrogenic side effects.
1. Introduction
Traditional Chinese medicines (TCMs) have been used as
medicines or health food supplements in China for over
thousand years. Historically, TCMs are prepared as decoc-
tions by a unique methodology with specific combinations
of different herbs as a formula. Among thousands of herbal
formulae, Danggui Buxue Tang (DBT) is a simple herbal
decoction that is composed of two herbs. DBT was first
described in Neiwaishang Bianhuo Lun by Li Dongyuan in
China in AD 1247. Li described that the DBT formula should
include 10 qian of Astragali Radix (AR), roots of Astragalus
membranaceus (Fisch.) Bunge or Astragalus membranaceus
(Fisch.) Bungevar. mongholicus (Bunge) P.K. Hsiao, and two
qian of Angelicae Sinensis Radix (ASR), roots of Angelica
sinensis (Oliv.) Diels. One qian equals about 3 grams. DBT is
prescribed for women in China as a remedy for menopausal
symptoms, which improves their health by raising the “Qi”
(vital energy) and nourishing the “blood” (body circulation).
Women in menopause suffer from hot flushes, sweating,
anxiety, and mood swings, as well as from an increased risk
for many health problems, such as loss of bone density mass
(osteoporosis) and cardiovascular disease. These problems
are largely due to the deficiency of ovarian hormones, espe-
cially estrogens [1]. Hormone replacement therapy (HRT)
had been used to alleviate menopausal symptoms for many
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years, but this treatment was associated with side effects, that
is, an increased risk of breast cancer, heart attacks, and strokes
[2]. In view of these clinical risks, extensive efforts have been
devoted to searching or developing new drugs that would
yield the benefits of hormone therapy but with minimal risk
[3]. TCM, containing thousands of medicinal herbs, is a
promising resource that could provide a perfect solution [4].
Indeed, some of the herbal products showed a pronounced
efficacy for menopausal symptoms and as a consequence
were widely used by women to relieve their menopausal
symptoms, for example, DBT [5–8]. In vitro experiments with
mammary gland [6] and bone [9] derived cells suggested
that at least some of the effectiveness of DBT is mediated
through estrogen receptor- (ER-) dependent mechanisms. In
order to support these observations in vivo, DBTwas tested in
the ovariectomized Wistar rat model for potential estrogenic
properties. Since DBT is a decoction that traditionally is con-
sumed as a tea, animals were supplemented by DBT through
the drinking water. Taking this approach, we performed a
three-day uterotrophic assay for revealing responses relevant
to contribute to the elucidation of the molecular mechanisms
of action of DBT, including organ weights and regulation of
gene expression.
2. Materials and Methods
2.1. PlantMaterials andDBT Preparation. Three-year-old AR
deriving from the roots ofA. membranaceus var.mongholicus
was collected from Shanxi province [10], and 2-year-old ASR
ofA. sinensiswas fromMinxian inGansu province [11].These
plant materials had been morphologically authenticated by
Dr. TinaDong, during the field collection.The corresponding
vouchers as forms of whole plants, voucher # 02-9-1 for
ASR and voucher # 02-10-4 for AR, were deposited in the
Center for Chinese Medicine, The Hong Kong University
of Science and Technology. 17𝛽-Estradiol (E
2
) was obtained
from Sigma-Aldrich (Deisenhofen, Germany). 250 g of sliced
AR and 50 g of sliced ASR were mixed (the ratio is 5 : 1)
and then boiled in 2,400mL (w : v = 1 : 8) of water for 2
hours, and then the decoction was filtered. The residues
were boiled in 1,800mL (w : v = 1 : 6) water for 1 hour. The
combined extracts were dried under vacuum and stored at
−20∘C. This extraction, following the ancient preparation,
was shown to be the best extracting condition [12]. Two
chemical markers in AR (calycosin and formononetin) and
two others in ASR (ferulic acid and ligustilide) were used to
standardize the chemical property of DBT. The standardized
DBT should contain no less than 0.186mg calycosin, 0.155mg
formononetin, 0.351mg ferulic acid, and 0.204mg ligustilide
per one g driedweight of DBT, as reported previously [5, 6, 8].
2.2. Animals. Juvenile female Wistar rats (130 ± 15 g) were
obtained fromHarlanWinkelmann (Borchen, Germany) and
were maintained under controlled conditions of temperature
(20∘C ± 1, relative humidity 50–80%) and illumination (12
hours light, 12 hours dark). All rats had free access to standard
rat diet (SSniff R10-Diet, SSniff GmbH, Soest, Germany)
and water. All animal husbandry and handling conditions
were according to the Institutional Animal Care and Use
Committee Guidelines in Germany.
2.3. Uterotrophic Assay. The estrogenicity was tested in the
3-day assay in ovariectomized rats according to the OECD
guideline 440 [13].The experimental procedures are schemat-
ically summarized in Figure 1. Briefly, following ovariectomy
and 14 days of endogenous hormonal decline, the animals
were treated for 3 days.The animals were randomly allocated
to the treatment with herbal extracts, positive control, or
vehicle groups (𝑛 = 6). DBT was administered orally
at the doses of 0.01 g/kg BW/d or 1 g/kg BW/dBW and E2
(1 𝜇g/kg BW/d; subcutaneous injection), which served as a
positive control. Animals were sacrificed by decapitation after
light anaesthesia with CO
2
inhalation. The wet weights of
uterus and livers were determined. Uteri and livers were
frozen in liquid nitrogen for the RNA preparation.
2.4. Total RNA Preparation and Reverse Transcription. The
total cytoplasmic RNA was extracted from the rat uteri by
the standard TRIzol method (Invitrogen, Grand Island, NY).
DNA residues were enzymatically eliminated by digestion
(Deoxyribonuclease I, Ambion, Foster City, CA), and the
removal was checked by PCR. Superscript II Reverse Tran-
scriptase (Invitrogen) and Oligo (dT) 12–18 were used for the
first-strand cDNA synthesis.
2.5. Quantitative Real-Time PCR. Quantitative real-time
PCR was carried out by Platinum Taq DNA polymerase
(Invitrogen) using the iCycler thermal cycler with iQ real-
time detection system. The reactions were run three times
in triplicate. After vortexing, 50 𝜇L aliquots of the mix were
pipetted in each well of the 96-well thin-wall PCR plate
(Bio-Rad, Hercules, CA). PCR reactions consisted of a first
denaturing cycle at 95∘C for 3min, followed by 50 cycles of
10 s at 95∘C, 15 s at 60∘C, and 30 s at 72∘C. Fluorescence was
quantified at the end of the 60∘C annealing step and product
identity was confirmed by a melting curve analysis (60–
95∘C). Primer sequences and amplicon sizes are summarized
in the Supplementary Table 1 in Supplementary Material
available online at http://dx.doi.org/10.1155/2014/438531. The
relative mRNA amounts of target genes were calculated after
normalization to an endogenous reference gene (cytochrome
C oxidase subunit 1, COX1). Results were expressed as relative
amounts of mRNA compared to the vehicle control animals
using the 2−ΔΔCT formula [14].
2.6. Statistical Analysis. Statistical analysis of the data in
this work was performed using two-way analysis of variance
followed by pairwise comparison of selected means using
the Student’s 𝑡-test. The criterion for significance was set to
∗
𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.001 as compared to the
control.
3. Results
3.1. Body Weight and Organ Wet Weights. The uterotrophic
response in ovariectomized rats was measured after 3 days
Evidence-Based Complementary and Alternative Medicine 3
Treatment groups
Negative control
Positive control
Compound/extract
Vehicle
Estradiol
DBT
DBT
Dose
Day 0: OvEx Day 14: treatment start Day 17: sacrifice
DBT0.01
DBT1
—
1𝜇g/kg BW/d, sc
0.01 g/kg BW/d, po
1g/kg BW/d, po
Figure 1: Experimental design. The figure summarizes the experimental design of the study. It schematically shows the workflow, as well as
the summary of the treatment groups included. bw: body weight; DBT: Danggui Buxue Tang; DBT
01
and DBT
1
: DBT at 0.01 and 1 g/kg bw/d.
of the drug treatment. DBT was applied at two doses of 0.01
(DBT
0.01
) and 1 (DBT
1
) g/kg BW/d. E
2
was used as positive
control at 1 𝜇g/kg BW/d, and the carrier castor oil was used
as a negative control. These treatments could not impact on
the body weight of animals (Figure 2(a)). Regarding the wet
weights, E
2
treatment for 3 days caused a significant increase
in uterine wet weight of more than 5-fold but did not affect
the liver weight (Figure 2(b)). The treatment with DBT, for
both concentrations of DBT
0.01
and DBT
1
, had no effect on
the weight of uterus and liver (Figure 2(b)). This observation
was in line with the expression of the mRNA of Ki-67,
a sensitive proliferation marker in uterus, which however
was unchanged after the DBT treatment (Figure 2(c)). The
expression of Ki-67 mRNA is highly stimulated in response
to the treatment with E
2
(Figure 2(c)). In liver, none of the
treatments resulted in a statistically significant impact on the
expression of Ki-67 (Figure 2(c)).
3.2. Estrogen-Associated Gene Expression in Uterus and Liver.
ThemRNA expression of ER𝛼 and ER𝛽 had been detected in
the rat uterus under all treatment conditions. After the treat-
ment with E
2
, the ER𝛼 and ER𝛽mRNAs showed the expected
significant downregulation, as compared to the control ani-
mals, while DBT application could not affect the mRNA
expression of ER𝛼 and ER𝛽 (Figure 3(a)). For ER action in
the uterus, some very sensitive marker genes are known to
monitor the estrogenic responses, that is, complement C3
(C3), calcium-binding protein 9 kDa (CaBP9k), and clusterin
(Clu). In uterus, E
2
treatment resulted in several hundredfold
significant upregulation of the mRNA encoding C3 and
CaBP9k, accompanied by a significant downregulation of
Clu mRNA expression (Figure 3(b)). Apparently, DBT was
capable of triggering very mild upregulation (not exceeding
5-fold) of the ER-dependent regulated genes C3 and CaBP9k.
The higher dose of DBT caused a downregulation of Clu
mRNA expression, which did not reach levels of statistical
significance because of the high standard deviation of the
mean value (Figure 3(b)).
The mRNA expression of ER𝛼 had been detected in the
rat liver under all treatment conditions. The autoregulatory
response of downregulation of ER𝛼 by E
2
did not reach the
level of statistical significance, whereas both DBT concen-
trations downregulated steady state mRNA levels of ER𝛼
in a statistically significant manner (Figure 4(a)). To assess
the expression of ER𝛼-dependent response genes in liver,
the expression levels of suitable liver-specific ER response
genes, that is, CaBP9k and insulin-like growth factor binding
protein I (IGFBP1), were determined. The E
2
treatment
resulted in an upregulation of CaBP9k mRNA expression
and in the downregulation of 1GFBP1 mRNA expression
in the liver (Figure 4(b)). The treatment with high dose of
DBT (DBT
1
) significantly reduced the expression of IGFBP1.
The increased expression of CaB9k was revealed after DBT
treatment at both concentrations but in both cases did
not reach the level of statistical significance because of the
variation (Figure 4(b)).
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Figure 2: The effect of E
2
or DBT on animal body and organ weight. (a) The ovariectomized animals were treated by E
2
(at 1 𝜇g/kg BW/d;
subcutaneous) or DBT (at 0.01 g/kg/d BW and 1 g/kg/d BW, orally) for three days; untreated ovariectomized animals served as a control group
(Ctrl.). The body weight of rats before sacrifice was determined.The wet organs including uteri and livers were weighed. (c)The regulation of
mRNA expression of the proliferation markers Ki-67 in uteri and livers was analyzed by semiquantitative real-time PCR analysis. Asterisks
indicate values significantly different from the respective controls. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.001.
3.3. Lipid Metabolism-Associated Gene Expression in Liver.
Because DBT is believed to increase “Qi” we investigated the
expression of genes associated with lipid metabolism. Being
the major site for lipid metabolism, liver function is linked
to obesity, which in turn is a risk factor for the diseases in
hormone-dependent organs, like breast cancer. We therefore
investigated the expression of Apolipoprotein A-I (Apo-
A1) as the major component of HDL-cholesterol and of
peroxisome proliferator-activated receptors (PPAR), which
represent lipid sensors and are in various ways involved in the
regulation of energymetabolism.The upregulation of PPAR𝛼
by DBT did not reach the level of statistical significance.
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Figure 3: Regulation of expression of estrogen receptors and estro-
gen response genes in the uteri. (a) The mRNA expression of
ER𝛼 and ER𝛽 in uteri and (b) the mRNA expression of estrogen
response genes including C3, CaBP9k, and Clu were analyzed
by quantitative real-time PCR analysis. Asterisks indicate values
significantly different from the respective controls. ∗𝑃 < 0.05, ∗∗𝑃 <
0.01, and ∗∗∗𝑃 < 0.001.
Regarding PPAR𝛾, DBT at a concentration of 1 g/kg BW/d
downregulated the expression of its mRNA (Figure 5(a)).
This downregulation was similar to that induced by E
2
. On
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Figure 4: Regulation of expression of estrogen receptors and
estrogen response genes in livers. The mRNA expression of ER𝛼
in livers (a) and the mRNA expression of the estrogen response
genes including CaBP9k and IGFBP1 in livers (b) were analyzed
by quantitative real-time PCR analysis. Asterisks indicate values
significantly different from the respective controls. ∗𝑃 < 0.05, ∗∗𝑃 <
0.01, and ∗∗∗𝑃 < 0.001.
the contrary, an effect which was clearly independent of
potential estrogenic properties of DBT was the pronounced
downregulation of PPAR𝛿mRNAexpression by both doses of
DBT (Figure 5(a)). These results clearly point to the fact that
DBT could regulate the expression of receptors intimately
involved in the regulation of the availability and consumption
of energy from fat through the modulation of expression
of the receptors of the PPAR family. As a potential link
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Figure 5: The gene expression of peroxisome proliferator-activated
receptors andApo-A1 in livers. (a)ThemRNA expression of PPAR𝛼,
PPAR𝛾, and PPAR𝛿 in livers was analyzed by quantitative real-time
PCR analysis. (b) The mRNA expression of Apo-A1 in livers was
analyzed by quantitative real-time PCR analysis. Asterisks indicate
values significantly different from the respective controls. ∗𝑃 < 0.05,
∗∗
𝑃 < 0.01, and ∗∗∗𝑃 < 0.001.
to complications of the metabolic syndrome, regulation of
cholesterol metabolism is of interest. We therefore assessed
the regulation of expression of Apo-A1 mRNA. The expres-
sion pattern is indicative of an estrogen-like property of
DBT in the concentration of 1 g/kg BW/d, which like E
2
downregulated Apo-A1 mRNA expression.
3.4. The Regulation of DBT on Aryl Hydrocarbon Receptor
Pathway in Uterus and Liver. Efficient detoxification is also
crucial for health. Aryl hydrocarbon receptor (AHR) is
known to trigger the expression of metabolizing/detoxifying
enzymes in liver and other tissues, which is acting in
a coordinated fashion with the battery of Nrf2-regulated
enzymes. Here, we investigated the expression of AhR, AhR
family members, and AhR responsive genes in uterus and
liver by DBT in comparison to E
2
. Overall, we detected a
tissue specific regulation of expression of AhR, AhR family
members, and response genes following treatment with DBT.
In uterus, AhR mRNA expression was strongly down-
regulated in response to E
2
, whereas no alteration was
apparent in response to DBT (Figure 6(a)). The expression of
aryl hydrocarbon receptor nuclear translocator 1 (ARNT 1)
mRNA, the coregulator of AHR, was downregulated by E
2
,
whereas DBT at the high dose leads to an upregulation of
ARNT1 mRNA levels in this organ. Regarding ARNT2, a
strong downregulation of mRNA expression resulted in the
uterus in response to E
2
treatment, an effect not detectable
in response to DBT (Figure 6(b)). Cytochrome P450 (family
1) A1 (Cyp1A1) and Glutathione-S-transferases Ya (GST-
Ya) are regarded as very sensitive response genes for AhR
function. Cyp1A1 mRNA levels in the uterus were strongly
downregulated by E
2
, an effect also detectable in response to
both doses of DBT, but at a lower degree (Figure 6(c)). GST-
Ya mRNA expression was only found to be upregulated in
response to E
2
. DBT treatment in both doses did not affect
GST-Ya mRNA expression in the uterus (Figure 6(c)).
In liver, a mild, statistically not significant upregulation
of AhR mRNA was detectable in response to E
2
treatment,
whereas DBT strongly induced AhR mRNA expression to
over 3-fold (Figure 7(a)). The mRNA level of ARNT1 could
only be induced by the low dose of DBT, but not for E
2
, and
high dose ofDBT. Furthermore, all three treatments appeared
to upregulate ARNT2 mRNA expression; however, none of
the values could reach the level of statistical significance
(Figure 7(b)). E
2
treatment resulted in a mild but not
significant upregulation of Cyp1A1 mRNA levels, whereas
DBT downregulates Cyp1A1 mRNA expression in a dose-
dependent manner. On the contrary, E
2
treatment did not
result in an alteration of mRNA expression of GST-Ya,
whereas DBT in high dose downregulated GST-Ya mRNA
expression in a statistically significant, dose dependent man-
ner (Figure 7(c)).
4. Discussion
Though DBT exhibited potential estrogenic effects in vitro
[5, 6, 8], the information on potential hormonal activities
of DBT in vivo is limited. It is well known that prolifera-
tion of endometrial cells is under the control of estrogens
and that the risk of endometrial carcinoma increases with
estrogen replacement therapy [15]. In addition, since natural
compounds with estrogen-like activities often exhibit organ
selective properties in vivo, we evaluated the uterotrophic
experiment performed in an organ dependent manner. We
assessed potential effects of DBT in the uterus, as an organ
of reproductive tract representing a classical target organ of
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Figure 6: Regulation of expression of AhR-related genes in uteri. (a) The mRNA expression of AhR in uteri, (b) the mRNA expression of
ARNT1 and ARNT2 in uteri, and (c) the mRNA expression of Cyp1A1 and GST-Ya in uteri were analyzed by semiquantitative real-time PCR
analysis. Asterisks indicate values significantly different from the respective controls. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.001.
estrogen action, and in the liver as the major metabolic site
being one of the organs expressing the ER𝛼 predominantly.
Therefore, to study the influence of DBT in the absence of
endogenous estrogen, we used ovariectomized female rats to
evaluate the ER selectivity of DBT in uterus and liver.
The results showed that DBT did not alter uterine and
liver wet weight or the level of expression of proliferation
markers and ERs at any of the investigated doses. For ER
action in the uterus, some very sensitive marker genes are
known which pick up estrogenic responses, that is, the
upregulation of C3 and CaBP9k and the downregulation of
Clu. C3 and CaBP9k could be upregulated by E
2
, whereas
Clu was downregulated by response to E
2
treatment in the
uterus. DBT did very mildly mimic estrogenic responses
for C3 and CaBP9k, but not for Clu. This is interesting as
upregulation of C3 and CaBP9k involves ERE-response ele-
ments [16, 17] whereas the precisemechanismof ERmediated
downregulation of Clu is not known. However, reflecting the
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Figure 7: Regulation of expression of AhR-related genes in livers. (a) The mRNA expression of AhR in livers, (b) the mRNA expression of
ARNT1 and ARNT2 in livers, and (c) the mRNA expression of Cyp1A1 and GST-Ya in livers were analyzed by semiquantitative real-time PCR
analysis. Asterisks indicate values significantly different from the respective controls. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.001.
transcription factor binding sites contained in Clu promoter
involvement of SP1- and AP-mediated processes is likely [18].
In parallel, the liver changes of expression of CaBP9k and
IGFBP1 had been established as estrogenic response markers,
although the overall response was by far lower than the
one detectable for CaBP9k or C3 in the uterus. In the liver,
DBT again exerted weak estrogenic properties in the 3-day
uterotrophic assay. Effects were only detectable using the
most sensitive gene expression markers of estrogen action.
Liver in addition is a major site for lipid metabolism
which is linked to obesity and which in turn is a risk factor
for the diseases in hormone dependent organs like breast
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cancer. We therefore investigated the expression of Apo-
A1 as the major component of HDL-cholesterol [19] and
of PPAR receptors which are in various ways involved in
the regulation of energy metabolism. They are also known
targets for natural compounds and binding to them improves,
for example, glucose uptake [20]. Our results clearly point
to the fact that DBT through modulation of expression of
the receptors of the PPAR family may contribute to the
regulation of the availability and utilization of energy from
fat.Numerous reviews summarize the regulation ofmetabolic
pathways following activation of PPARs [21, 22], a topic
which is out of focus of this paper. However, two features
of our results regarding PPAR deserve discussion. A strong
downregulation of PPAR𝛿 in response to DBT was observed.
In this connection it is important to mention that PPAR𝛿
responded to DBT treatment apparently in an estrogen/ER
independent manner.The functional consequences of down-
regulation of PPAR𝛿 expression by DBT need to remain open
at this point; however, it is not due to an autoregulatory
downregulation of PPAR𝛿 following binding of constituents
of DBT, because DBT neither stimulated PPAR𝛿 nor PPAR𝛾-
dependent reporter gene activation in a transient transfection
assay (data not shown). However, activation of a PPAR𝛿
dependent signaling cascade by DBT would be interesting,
as PPAR𝛿 is the major regulator for mobilization of fat
and energy expenditure from fat [22] and because of this
phenotype potentially linked to obesity and its prevention.
In contrast, PPAR𝛾 at least at a high dose of DBT
responded in an estrogen-like manner by being downreg-
ulated. One important feature in addition to its insulin-
sensitizing properties of PPAR𝛾 is that it determines stem cell
fate of mesenchymal stem cells. Skeletal effects of PPAR𝛾 are
well established in the meantime. It activates adipogenic dif-
ferentiation, thereby inhibiting osteogenic differentiation [23,
24].This situation would be disadvantageous for menopausal
women and this is why downregulation of PPAR𝛾 by DBT
may point to a beneficial effect.
It is long known that the AhR pathway triggers the
expression of metabolizing enzymes in the liver and in other
tissues mostly in a coordinated fashion with the battery of
Nrf2 regulated enzymes [25], thereby contributing to the
detoxification process. We recently showed that there exists
a link between estrogen function and regulation of AhR
and members AhR signaling cascade in the uterus [26, 27].
Therefore, we comparatively investigated the regulation of
expression of AhR, AhR family members, and AhR response
genes in uterus and liver by DBT in comparison to estradiol.
First, we confirmed the estrogenic response pattern of the
AhR gene battery members [26]. For DBT treatment we
overall detected a tissue specific regulation of expression of
AhR, AhR family members, and response genes following
treatment with DBT. Cyp1A1 and GST-Ya, in addition to
being members of first (Cyp1A1) and second pass (GST-Ya)
metabolic enzymes, are regarded as very sensitive response
genes regarding crosstalk mechanisms of involving AhR and
ER pathways [26] and here were tested too. As an interest-
ing observation DBT treatment exhibited an estrogen-like
response pattern for regulation of Cyp1A1 expression, but
not for GST-Ya, indicative of the fact that DBT function in
the liver is associated with both estrogen-like and estrogen-
independent properties.The same holds presumably for AhR
triggered responses. For the future it will be interesting to
see whether DBT and/or its constituents will trigger AhR-
mediated reporter gene activities.
In addition, although weakly, we found ARNTmolecules
to be upregulated by DBT in the liver. This is interesting
as some of the authors involved in this paper recently
described the upregulation of HIF1𝛼 by DBT ultimately
leading to upregulation of erythropoietin [8]. ARNT1 is also
called HIF1𝛽 and represents the heterodimeric dimerization
partner of HIF1𝛼 in mediation of its nuclear responses [28].
In other words, we show here that DBT upregulates not only
HIF1𝛼 but also HIF1𝛽/ARNT1 thereby potentially supporting
the effect of HIF1𝛼 on erythropoiesis.
In summary, we showed for the first time that DBT
regulates the mRNA levels of members of the AhR signaling
cascade, thereby exhibiting both estrogen-like and estrogen
receptor independent activities, presumably leading to a
distinct pattern of detoxificationmechanisms.Thefinalmajor
result was that effects of DBT appear to be organ selective,
influencing functions relevant to menopausal health. On the
safety side there was no indication for estrogen dependent
stimulation of proliferation within organs of the repro-
ductive tract. Regarding efficacy DBT exhibits weak estro-
genic properties and regulates the expression of functionally
interconnected lipid sensors comprising amongst others the
PPAR and AhR families of molecules [29, 30], the latter
establishing a link to detoxification and energy metabolism.
We hypothesize that DBT therefore may have properties
which directly and indirectly impact on menopausal health.
Abbreviations
TCM: Traditional Chinese medicine
DBT: Danggui Buxue Tang
ASR: Angelicae Sinensis Radix
AR: Astragali Radix
AhR: Aryl hydrocarbon receptor
Apo-A1: Apolipoprotein A-1
E
2
: 17𝛽-Estradiol
ER: Estrogen receptor
ERE: Estrogen response element
HRT: Hormone replacement therapy
PPAR: Peroxisome proliferator-activated receptor.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Acknowledgments
This research was supported by Grants from Research
Grants Council of Hong Kong (HKUST 6419/06M and
N HKUST629/07, 662608), Croucher Foundation (CAS-
CF07/08.SC03) to Karl W. K. Tsim, and German Research
Foundation (DFG Vo410/6-5) and German Academic
Exchange Service (DAAD 50023165) to Günter Vollmer.
10 Evidence-Based Complementary and Alternative Medicine
Contributors of TU-Dresden acknowledge support by
the German Research Foundation and the Open Access
Publication Funds of the TU-Dresden.
References
[1] B. L. Harlow and L. B. Signorello, “Factors associated with early
menopause,”Maturitas, vol. 35, no. 1, pp. 3–9, 2000.
[2] J. E. Rossouw, G. L. Anderson, R. L. Prentice et al., “Risks and
benefits of estrogen plus progestin in healthy postmenopausal
women: principal results from the women’s health initiative
randomized controlled trial,” Journal of the American Medical
Association, vol. 288, no. 3, pp. 321–333, 2002.
[3] A. Brzezinski and A. Debi, “Phytoestrogens: the “natural”
selective estrogen receptor modulators?” European Journal of
Obstetrics & Gynecology and Reproductive Biology, vol. 85, pp.
47–51, 1999.
[4] M. G. Glazier and M. A. Bowman, “A review of the evidence
for the use of phytoestrogens as a replacement for traditional
estrogen replacement therapy,” Archives of Internal Medicine,
vol. 161, no. 9, pp. 1161–1172, 2001.
[5] T. T. X. Dong, K. J. Zhao, Q. T. Gao et al., “Chemical and biolog-
ical assessment of a Chinese herbal decoction containing Radix
Astragali and Radix Angelicae Sinensis: determination of drug
ratio in having optimized properties,” Journal of Agricultural
and Food Chemistry, vol. 54, no. 7, pp. 2767–2774, 2006.
[6] Q. T. Gao, R. C. Y. Choi, A. W. H. Cheung et al., “Danggui
buxue tang—aChinese herbal decoction activates the phospho-
rylations of extracellular signal-regulated kinase and estrogen
receptor 𝛼 in cultured MCF-7 cells,” FEBS Letters, vol. 581, no.
2, pp. 233–240, 2007.
[7] C.C.Wang,K. F. Cheng,W.M. Lo et al., “A randomized, double-
blind, multiple-dose escalation study of a Chinese herbal
medicine preparation (Dang Gui Buxue Tang) for moderate
to severe menopausal symptoms and quality of life in post-
menopausal women,” Menopause, vol. 20, no. 2, pp. 223–231,
2013.
[8] K. Y. Z. Zheng, R. C. Y. Choi, H. Q. H. Xie et al., “The expression
of erythropoietin triggered by Danggui Buxue Tang, a Chinese
herbal decoction prepared from Radix Astragali and Radix
Angelicae Sinensis, is mediated by the hypoxia-inducible factor
in cultured HEK293T cells,” Journal of Ethnopharmacology, vol.
132, no. 1, pp. 259–267, 2010.
[9] R. C. Y. Choi, Q. T. Gao, A. W. H. Cheung et al., “A Chinese
herbal decoction, danggui buxue tang, stimulates proliferation,
differentiation and gene expression of cultured osteosarcoma
cells: genomic approach to reveal specific gene activation,”
Evidence-based Complementary and Alternative Medicine, vol.
2011, Article ID 307548, 13 pages, 2011.
[10] X. Q. Ma, Q. Shi, J. A. Duan, T. T. X. Dong, and K. W. K. Tsim,
“Chemical analysis of Radix Astragali (Huangqi) in China:
a comparison with its adulterants and seasonal variations,”
Journal of Agricultural and Food Chemistry, vol. 50, no. 17, pp.
4861–4866, 2002.
[11] K. J. Zhao, T. T. X. Dong, P. F. Tu, Z. H. Song, C. K. Lo, and K.W.
K. Tsim, “Molecular genetic and chemical assessment of radix
Angelica (Danggui) in China,” Journal of Agricultural and Food
Chemistry, vol. 51, no. 9, pp. 2576–2583, 2003.
[12] Z. H. Song, Z. N. Ji, C. K. Lo et al., “Chemical and bio-
logical assessment of a traditional Chinese herbal decoction
prepared from radix astragali and radix angelicae sinensis:
orthogonal array design to optimize the extraction of chemical
constituents,” PlantaMedica, vol. 70, no. 12, pp. 1222–1227, 2004.
[13] J. Kanno, L. Onyon, S. Peddada, J. Ashby, E. Jacob, and J. W.
Owens, “The OECD program to validate the rat uterotrophic
bioassay. Phase 2: dose-response studies,” Environmental Health
Perspectives, vol. 111, no. 12, pp. 1530–1549, 2003.
[14] J. Winer, C. K. S. Jung, I. Shackel, and P. M. Williams,
“Development and validation of real-time quantitative reverse
transcriptase-polymerase chain reaction for monitoring gene
expression in cardiac myocytes in vitro,” Analytical Biochem-
istry, vol. 270, no. 1, pp. 41–49, 1999.
[15] K. Ito, “Hormone replacement therapy and cancers: the bio-
logical roles of estrogen and progestin in tumorigenesis are
different between the endometrium and breast,” Tohoku Journal
of Experimental Medicine, vol. 212, no. 1, pp. 1–12, 2007.
[16] J. D. Norris, D. Fan, B. L. Wagner, and D. P. McDonnell, “Iden-
tification of the sequences within the human complement 3
promoter required for estrogen responsiveness provides insight
into the mechanism of tamoxifen mixed agonist activity,”
Molecular Endocrinology, vol. 10, no. 12, pp. 1605–1616, 1996.
[17] G.-S. Lee, K.-C. Choi, H.-J. Han, and E.-B. Jeung, “The clas-
sical and a non-classical pathways associated with NF-𝜅B are
involved in estrogen-medicated regulation of Calbindin-D9k
gene in rat pituitary cells,” Molecular and Cellular Endocrinol-
ogy, vol. 277, no. 1-2, pp. 42–50, 2007.
[18] P. Wong, D. Taillefer, J. Lakins, J. Pineault, G. Chader, and
M. Tenniswood, “Molecular characterization of human TRPM-
2/clusterin, a gene associated with spermmaturation, apoptosis
and neurodegeneration,” European Journal of Biochemistry, vol.
221, no. 3, pp. 917–925, 1994.
[19] R. Geis, P. Diel, G. H. Degen, and G. Vollmer, “Effects of
genistein on the expression of hepatic genes in two rat strains
(Sprague-Dawley and Wistar),” Toxicology Letters, vol. 157, no.
1, pp. 21–29, 2005.
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